Clinical Trials Logo

Filter by:
NCT ID: NCT06056362 Recruiting - Clinical trials for Neuroendocrine Tumors

Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors

Start date: March 23, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This prospective, single-center, double-blinded study investigates the biodistribution, dosimetry, safety, and diagnostic ability of Al18F-NOTA-LM3 in patients with well-differentiated neuroendocrine tumors. And compares the diagnostic ability of Al18F-NOTA-LM3 with 68Ga-DOTATATE PET/CT and 68Ga-NODAGA-LM3 PET/CT. Clinical management will also be compared using different imaging modalities.

NCT ID: NCT06056336 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

Start date: September 7, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved survival outcomes.

NCT ID: NCT06056232 Not yet recruiting - Emotional Distress Clinical Trials

Mechanisms of Mindfulness Intervention: Distress Tolerance Dose Manipulation

Start date: October 5, 2023
Phase: N/A
Study type: Interventional

This study hopes to: 1. explore whether an increase in the dosage of distress tolerance intervention corresponds to greater effectiveness of mindfulness intervention in alleviating emotional distress. 2. explore whether distress tolerance mediates the effects of mindfulness intervention on alleviating emotional distress.

NCT ID: NCT06056115 Recruiting - Lung Adenocarcinoma Clinical Trials

Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Brain metastasis of lung cancer is one of the most important metastasis pathways in patients with life-threatening diseases. This study explore the efficacy and safety of Tislelizumab combining with platinum-containing drug chemotherapy in the first-line treatment of Lung Adenocarcinoma With Asymptomatic Brain Metastatic. Meanwhile, Related biomarkers were explored to provide theoretical basis for efficacy evaluation and resistance mechanism.

NCT ID: NCT06056050 Recruiting - Tetanus Clinical Trials

A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)

Start date: December 6, 2023
Phase: Phase 1
Study type: Interventional

Pertussis is an acute respiratory infectious disease caused by Bordetella pertussis, diphtheria is an acute upper respiratory infectious disease caused by Gram-positive Corynebacterium diphtheriae, and tetanus is a highly fatal disease caused by Clostridium tetani infection. Currently, there is no clinical trial registration of Diphtheria, tetanus, and pertussis (DPT) vaccine applicable to ≥6 years of age in China, therefore, the five-component acellular DPT combination vaccine developed by our research has a promising future.

NCT ID: NCT06055816 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Start date: September 28, 2023
Phase: Phase 2
Study type: Interventional

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

NCT ID: NCT06055777 Recruiting - Infections Clinical Trials

Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts

Start date: September 7, 2023
Phase: Phase 1
Study type: Interventional

This phase 1 study was designed to evaluate the safety and tolerability of SZEY-2108 in single and multiple intravenous infusions, the pharmacokinetic profile of SZEY-2108 after single and multiple intravenous infusions, and the effect of exposure to SZEY-2108 after a single intravenous infusion on QT/QTc interval. Metabolites in each biological matrix (blood, urine, feces) and excretion characteristics (feces) after SZEY-2108 were analyzed.

NCT ID: NCT06055738 Recruiting - Clinical trials for Locally Advanced Cervical Cancer

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Start date: October 9, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single arm, phase II clinical study to evaluate the efficacy and safety of Zimberelimab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer.

NCT ID: NCT06055595 Active, not recruiting - Pregnancy Related Clinical Trials

Genetic Factors and CP Pregnancy Outcomes

Start date: January 2010
Phase:
Study type: Observational [Patient Registry]

To explore the impact of chronic pancreatitis (CP) susceptibility genes on pregnancy outcomes.

NCT ID: NCT06055452 Recruiting - Hypertension Clinical Trials

Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Start date: January 19, 2024
Phase: Phase 4
Study type: Interventional

In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. We sought to comprehensively evaluate the effect of engagliflozin on the structure and function and explore its underlying mechanisms.